Clinical trials: Atypical Parkinsonism
Progressive Supranuclear Palsy, Corticobasal Degeneration
Wellness in PSP and CBD
The goal of this interventional study is to evaluate the feasiblity and effectiveness of a multimodal lifestyle program for individuals living with Progressive Supranuclear Palsy or Corticobasal Deneration.
- Trial name
- NCT07844655
- Testing
- Exercise and Peer Support
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Silke Cresswell
Neurodegenerative Diseases, Parkinson Disease
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal…
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Synucleinopathies, Lewy Body Disease
- Trial name
- MARKERS-NDD (NCT06596746)
- Testing
- Observation
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Casa di Cura San Raffaele Cassino
Parkinson Disease, Atypical Parkinsonism
A Model of Hospital-Territory Management Coordinated by a Case Manager to Improve the Care of Patients With Parkinsonism.
The present multicenter randomized study investigates whether the management of patients with parkinsonism by a nurse specialist (case-manager) can significantly improve patients' quality of life over 12 months, compared to…
- Conditions
- Parkinson Disease, Atypical Parkinsonism, Secondary Parkinsonism, Nurse-Patient Relations
- Trial name
- PROUD (NCT05273957)
- Testing
- Case Manager, Standard-of-care
- Where
- 2 sites in Italy
- Volunteers
- 121 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Parkinson's Disease, Parkinson-Dementia Syndrome
Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in the Dementia of Parkinson's Disease
The PET tracer Fluoro-ethyl-methyl-amino-naphthyl-ethylidene-malononitrile ([F18]-FDDNP) has a specific affinity for lesions containing tau protein and beta-amyloid The study consists of two phases In a first transversal phase, 8…
- Trial name
- NCT02243982
- Testing
- [F18]-FDDNP
- Where
- Spain
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Parkinson's Disease, Parkinsonian Disorders
Gait Analysis in Neurological Disease
The purpose of this study is to investigate whether speed-dependent measures of gait (so called gait signatures) can be identified in patients with neurological conditions that affect gait, particularly in subjects with…
- Conditions
- Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy
- Trial name
- NCT02994719
- Testing
- Anti-Parkinson medication, Deep Brain Stimulation
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Progressive Supranuclear Palsy, PSP
AMX0035 and Progressive Supranuclear Palsy
A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an…
- Conditions
- Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
- Trial name
- ORION (NCT06122662)
- Testing
- AMX0035
- Where
- 62 sites in United States, France and 3 more
- Volunteers
- 139 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Parkinson Disease, Parkinsons Disease With Dementia
A Pilot Study to Explore the Role of Gut Flora in Parkinson's Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Parkinson's Disease.
- Conditions
- Parkinson Disease, Parkinsons Disease With Dementia, Parkinson-Dementia Syndrome, Parkinson Disease 2
- Trial name
- NCT04148326
- Testing
- No Intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Rare Diseases
European Registry on Rare Neurological Diseases
The recent implementation of European Reference Networks for Rare Diseases (ERNs) is an unprecedented move to improve the care of patients suffering from rare health disorders by transnational collaboration.
- Trial name
- ERN-RND reg (NCT04319796)
- Testing
- Data set as defined by the ERN Research Workgroup of the European Commission
- Volunteers
- 5,000 people
- Sponsor
- University Hospital Tuebingen
Rapid Eye Movement Sleep Behavior Disorder
RBD Longitudinal as Prognostic for PD
Purpose - to validate a combination of biological and clinical markers in the rapid-eye-movement (REM) sleep behavior disorder (RBD) population as indicative of the pre-symptomatic stage of Parkinson's disease (PD).
- Trial name
- RBD6YR (NCT00817726)
- Where
- United States
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Parkinson Disease, Osteoporosis
Trial of Parkinson's And Zoledronic Acid
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and…
- Conditions
- Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism
- Trial name
- TOPAZ (NCT03924414)
- Testing
- Zoledronic Acid 5Mg/Bag 100Ml Inj
- Where
- 77 sites in United States
- Volunteers
- 2,721 people
- Sponsor
- California Pacific Medical Center Research Institute
Parkinson's Disease and Parkinsonism, Dysphagia
Clinical Efficacy and Mechanism of tDCS for Dysphagia in PD
This study aims to verify transcranial direct current stimulation(tDCS) efficacy for Parkinson's disease (PD)-related dysphagia and its mechanism.
- Trial name
- NCT07153692
- Testing
- tDCS, Conventional Dysphagia Treatment
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Wang Ping
Progressive Supranuclear Palsy, Multiple System Atrophy
NMR Based Metabolomic Study of Serum Biomarkers in Patients With Parkinson's Disease and Atypical Parkinsonian Syndrome
At present, the diagnosis of Parkinsons disease(PD) mainly relies on clinical symptoms and is easily confused with atypical Parkinsonian syndrome(APS) in the early stages. There is an urgent need for reliable biomarkers.
- Conditions
- Progressive Supranuclear Palsy, Multiple System Atrophy, Parkinson's Disease
- Trial name
- NCT06490926
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University Union Hospital
Multiple System Atrophy
Study of ATH434 in Participants with Multiple System Atrophy
This study will assess the safety and efficacy of ATH434 in participants with Multiple System Atrophy
- Trial name
- NCT05109091
- Testing
- ATH434 dose level 1, ATH434 dose level 2
- Where
- 23 sites in United States, Australia and 4 more
- Volunteers
- 77 people
- Sponsor
- Alterity Therapeutics
Atypical Parkinsonism, Parkinson Disease (PD)
Standard Optimization of Stem Cells in Parkinson's Disease and Atypical Parkinsonism
The purpose of this study is to measure outcomes using intranasal and intravenous autologous bone marrow mesenchymal stem cells (BM-MSCs) for Parkinson Disease (PD) and Parkinson's Plus (PPS) patients.
- Trial name
- SO-ASC-INIVAT (NCT06858254)
- Testing
- Autologous mesenchymal stem cells
- Volunteers
- 60 people
- Sponsor
- Apeiron Research Center
Dementia, Alzheimer Disease
The Swedish BioFINDER 2 Study
The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g.
- Conditions
- Dementia, Alzheimer Disease, Parkinson Disease, Lewy Body Disease
- Trial name
- BioFINDER2 (NCT03174938)
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau
- Where
- 2 sites in Sweden
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Parkinson Disease, Atypical Parkinsonism
Spinal Cord Stimulation for Gait in Parkinson Disease
Balance and gait impairment increases the risk of falls and contributes to a reduced quality of life and shorter survival in Parkinson disease (PD) and atypical Parkinsonism patients.
- Trial name
- NCT03079310
- Testing
- Spinal cord stimulation
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Western University, Canada
Neuroaxonal Dystrophy, Atypical
Phenotypic Description of Patients With Atypical Clinical Forms of PLA2G6 Mutations
Mutations in the PLA2G6 gene are well known in the classical phenotype called infantile neuro-axonal dystrophy (INAD), a severe neurodegenerative disease starting in infancy with homogeneous clinical, radiological…
- Trial name
- ATYPICPLA2G6 (NCT05440994)
- Where
- 7 sites in France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Clermont-Ferrand
Hypotension Symptomatic, Parkinson's Disease
Epidural Electrical Stimulation to Support Hemodynamic Management in Individuals With Parkinson's Disease
The PD-HemON study aims to evaluate the safety and preliminary efficacy of ARC-IM Therapy (Epidural Electrical Stimulation) to support hemodynamic management in people with typical and atypical Parkinson's Disease, who suffer…
- Conditions
- Hypotension Symptomatic, Parkinson's Disease, Orthostatic Hypotension, Dysautonomic, Multiple System Atrophy (MSA) With Orthostatic Hypotension
- Trial name
- PD-HemON (NCT06920134)
- Testing
- ARC-IM Investigational System
- Where
- Switzerland
- Volunteers
- 5 people
- Sponsor
- Ecole Polytechnique Fédérale de Lausanne
Parkinson's Disease, Atypical Parkinsonism
Parkinson's Disease, Diagnostic Observations (PADDO)
Background: Parkinson's Disease and the Atypical Parkinsonian Disorder (like Multiple System Atrophy, Progressive Supranuclear Palsy, Corticobasal Degeneration, Lewy Body Dementia) are disease entities with partly common…
- Trial name
- PADDO (NCT01249768)
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Radboud University Medical Center
Multiple System Atrophy, Dementia With Lewy Bodies (DLB)
Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)
This goal of this observational study is to clarify the variations in the natural course of atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rate of motor and non-motor symptoms and…
- Conditions
- Multiple System Atrophy, Dementia With Lewy Bodies (DLB), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
- Trial name
- NCT07805967
- Testing
- We did not apply any interventions; only observational research was conducted.
- Where
- 20 sites in China
- Volunteers
- 500 people
- Sponsor
- Second Affiliated Hospital of Soochow University